At Cortado Ventures, we back entrepreneurs that are inventing the future, and we are thrilled about our investment in Moat Biotechnology. Moat’s technology is based on a next-generation adenovirus platform from the Mayo Clinic. Our General Partner Mike Moradi articulates our commitment to Moat Biotechnology, the first western company to demonstrate a successful inhaled COVID booster in a human clinical trial. Read More.